Loading stock data…
$25.28-0.29 (-1.13%)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Adaptive Biotechnologies Corporation in the Healthcare sector is trading at $25.28 with a market capitalization of $4.6B. Wall Street consensus targets $29.44 (8 analysts), implying a +16.4% move over the next 12 months. The stock is currently 18% below its 52-week high of $30.74, remaining 33.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.55M↑ | $70.87M↓ | $71.68M↓ | $93.97M↑ | $58.88M |
| Gross Profit | $51.39M↓ | $52.17M↓ | $53.46M↓ | $75.82M↑ | $40.88M |
| Operating Income | -$15.77M↑ | -$19.21M↓ | -$12.77M↓ | $10.29M↑ | -$25.04M |
| Net Income | -$39.79M↓ | -$20.03M↓ | -$13.58M↓ | $9.55M↑ | -$25.61M |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, ...